Marcaine 0,5 % Adrenaline

Bupivacaine hydrochloride, the active ingredient in Marcaine 0,5 % Adrenaline, is a local anesthetic presented as a 0.5 % injection solution for epidural and infiltration use. It provides regional or local anesthesia for surgical procedures, labor analgesia, and other invasive interventions in adult patients.

GNH USA supplies Marcaine 0,5 % Adrenaline as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support across multiple regions.

Marcaine 0,5 % Adrenaline, a combination local anesthetic and vasoconstrictor, is employed in procedures requiring regional or infiltration anesthesia. - Surgical procedures: provides localized numbness to facilitate incision, tissue dissection and postoperative pain control. - Labor and delivery: delivers epidural analgesia to reduce pain during childbirth while maintaining maternal consciousness. - Minor invasive interventions: enables infiltration anesthesia for dental work, skin suturing and small orthopedic procedures.

Adverse reactions to Marcaine 0,5 % Adrenaline are generally related to the local anesthetic component or the epinephrine vasoconstrictor.

Common Side Effects: - Transient hypotension: mild drop in blood pressure shortly after injection. - Injection site pain: localized discomfort at the administration site. - Metallic taste: brief taste disturbance after infiltration.

Serious or Rare Side Effects: - Cardiac arrhythmias: irregular heart rhythm that may be life‑threatening. - Severe hypotension: marked blood pressure fall requiring intervention. - Allergic reactions: rash, itching, bronchospasm or anaphylaxis.

When using Marcaine 0,5 % Adrenaline, clinicians should observe several safety measures to minimize risks. - Cardiac history: avoid or use with caution in patients with significant conduction disorders or recent myocardial infarction. - Beta‑blocker therapy: monitor for exaggerated hypertensive response due to epinephrine. - Dose limits: adhere to recommended maximum bupivacaine dose to prevent systemic toxicity. - Pregnancy: consider risk‑benefit; category B indicates no proven fetal harm but use only if clearly needed. - Pediatric use: adjust dose carefully based on weight and monitor for signs of toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Marcaine 0,5 % Adrenaline may interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate severe hypertension from epinephrine. - Non‑selective β‑blockers: may enhance epinephrine‑induced vasoconstriction and raise blood pressure. - Other local anesthetics: additive toxicity risk, especially with bupivacaine.

Moderate Interactions (Monitor Closely): - CNS depressants: may potentiate central nervous system effects of bupivacaine. - Diuretics: may alter plasma levels of bupivacaine, requiring dose adjustment.